Denali Therapeutics announced clinical progress across three lysosomal storage disorder programs using its proprietary Enzyme TransportVehicle platform. Tividenofusp alfa (DNL310) for Hunter syndrome showed sustained biomarker reductions and clinical improvements through Week 201, with an FDA PDUFA decision expected April 5, 2026. DNL126 for Sanfilippo syndrome type A demonstrated an 80% mean reduction in cerebrospinal fluid heparan sulfate in preliminary Phase 1/2 data. DNL952 for Pompe disease entered Phase 1 testing with preclinical data showing improved glycogen reduction in muscle and brain.

Denali Therapeutics announced it will present clinical and preclinical data from its Enzyme TransportVehicle (ETV) programs at the 2026 WORLDSymposium in February. The company will showcase continued Phase 1/2 data for tividenofusp alfa (DNL310) for Hunter syndrome, which is under FDA Priority Review with a decision expected by April 5, 2026, as well as preliminary data from DNL126 for Sanfilippo syndrome type A and Phase 1 study design for DNL952 for Pompe disease.

Denali Therapeutics announced publication of Phase 1/2 trial results for tividenofusp alfa (DNL310), an investigational enzyme replacement therapy for Hunter syndrome (MPS II) that crosses the blood-brain barrier. The study showed significant reduction in key disease biomarkers, normalization of heparan sulfate levels in cerebrospinal fluid and urine, and improvements in clinical endpoints including cognition, adaptive behavior, and hearing. The FDA is conducting Priority Review of the Biologics License Application with a decision expected by April 5, 2026.

Denali Therapeutics plans to raise approximately $200 million through a public offering of 9,142,857 common stock shares and pre-funded warrants at $17.50 per share, with underwriters including Goldman Sachs, J.P. Morgan, Morgan Stanley, and Jefferies.

Denali Therapeutics appointed Tim Van Hauwermeiren to its Board of Directors and announced the departure of Chief Medical Officer Carole Ho to Eli Lilly, with Peter Chin assuming the Acting Chief Medical Officer role.

The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.

Denali Therapeutics has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II). The company also has positive ongoing interactions with the FDA on the development of DNL126 for Sanfilippo syndrome type A (MPS IIIA) through the START program.

The mucopolysaccharidosis market is witnessing a surge in innovation, driven by cutting-edge gene therapies, enzyme replacement treatments, and novel drug developments. The market is poised for exponential growth with rising awareness, early diagnosis, and increasing investments in rare disease research.

The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.

The global neuroregeneration therapy market is expected to grow significantly, driven by advancements in regenerative medicine and the rising prevalence of neurological disorders. Key players are investing heavily in R&D, leading to innovative therapies and clinical trials that are accelerating market expansion.

Biogen reported strong Q2 results, beating earnings and revenue estimates. The company raised its 2024 guidance, driven by growth in new products like Leqembi and Skyclarys, offsetting declines in key multiple sclerosis drugs. However, the termination of a program with Denali Therapeutics weighed on the stock.

Denali Therapeutics director Steve E. Krognes sold over $678,000 worth of company stock in two separate transactions. The sales were executed under a Rule 10b5-1 trading plan, and Krognes still holds a substantial stake in the company.